Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.63 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.63 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.63 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.52 |
| ▸ | CDK8 | P49336 | 3/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.48 |
| ▸ | CLK1 | P49759 | 2/20 | 0.48 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.48 |
| ▸ | KIT | P10721 | 5/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | SGK1 | O00141 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798904 | 0.84 | AXL (0.68) | MAP3K11NTRK1CDK8KITAXL | |
| SCHEMBL13746035 | 0.81 | CDK8 (0.74) | MAPK8MAPK9MAPK10MAP3K11NTRK1 | |
| SCHEMBL12763222 | 0.81 | CDK8 (0.47) | MAP3K11NTRK1CDK8DYRK1ACLK1 | |
| SCHEMBL13745264 | 0.80 | CDK8 (0.72) | MAPK8MAPK9MAPK10MAP3K11NTRK1 | |
| SCHEMBL8319981 | 0.80 | MAPK8 (0.67) | MAPK8MAPK9MAPK10MAP3K11NTRK1 | |
| SCHEMBL13620697 | 0.79 | AXL (0.76) | MAPK8MAPK9MAPK10MAP3K11NTRK1 | |
| SCHEMBL8321034 | 0.79 | MAPK8 (0.65) | MAPK8MAPK9MAPK10MAP3K11NTRK1 | |
| SCHEMBL1516651 | 0.79 | NTRK1 (0.59) | NTRK1CDK8DYRK1ACLK1KIT | |
| SCHEMBL8298162 | 0.78 | MAPK8 (0.72) | MAPK8MAPK9MAPK10MAP3K11NTRK1 | |
| SCHEMBL8256110 | 0.78 | MAPK8 (0.64) | MAPK8MAPK9MAPK10MAP3K11NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | MAPK8 50/4885MAPK9 43/4885MAPK10 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.